



10 May 2022

Investor briefing session - Update



Key details:



Now at Thursday 12 May 2022, 11:30am (AEST)



Speakers: Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO)



Hosted by Market Eye, the virtual group briefing, and Q&A session is being held via Zoom (registration details below)

Zelira Therapeutics Limited (ASX:ZLD, OTCQB:ZLDAF) ('Zelira' or the 'Company') wishes to advise the details of the virtual group briefing with Chairman Osagie Imasogie and Global CEO Oludare Odumosu, investors are invited to attend have changed and will now be held on Thursday, 12 May 2022 at 11:30am AEST.

Hosted by Market Eye, Mr Imasogie and Mr Odumosu will provide an update on the Company's recent operational progress, the proposed acquisition of Health House International Ltd (ASX: HHI) and the recent share consolidation

Shareholders will have an opportunity to ask questions at the end of the briefing.

Register to attend via the link below:

https://us02web.zoom.us/webinar/register/WN_2JFI8sWQmqzcFVOgs_3eQ

This announcement was authorised for release by the Chairman of the Board of Zelira Therapeutics Limited.



For further information
please contact:

Company

Dr Oludare Odumosu
Managing Director & CEO

+1 909 855 0675

oodomosu@zeliratx.com

Investors

Market Eye Pty Ltd
Melbourne | Sydney

+61 3 9591 8900

Fax: +61 3 9591 8999

www.marketeye.com.au

ABN 54 137 305 527

About Zelira Therapeutics
(www.zeliratx.com)

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA

+61 8 6558 0886

Fax: +61 8 6316 3337

enquiries@zeliratx.com

www.zeliratx.com

ACN 103 782 378

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462

United States Of America

+1 484-630-0650

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global therapeutic medical cannabinoid company with access to the world's largest and fastest growing cannabinoid medicine markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets.

The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Pennsylvania and have been licensed in Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol™ has successfully completed the world's first Phase 1b clinical trial for chronic insomnia where it was found to be a safe and effective treatment.

In 2020, Zelira partnered with SprinJene® Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.